RECO UP5 Beverly is the most powerful and complete formula ever created of Branched Chain Amino Group 4:1:1 (4 parts of Leucine, 1 of Isoleucine and 1 of Valine): a powerful and advanced combination of Branched Amino acids that are important for muscle growth and recovery; to this powerful combination we have added L-Glutamine to protect against the loss of muscle mass in high intensity training through increased capacity of blood oxygenation and energy recovery post workout immediate strengthening your immune system to 300%. Citrulline Malate will provide energy, stamina and energy retracing muscle fatigue in athletes adapting high strength (athletics, cycling, trail runners, swimming, etc …)
This combination is superior to the usual ratio of amino acids in the market, allowing you to absorb a greater amount of amino acids in less time and promote your resilience after training, reducing muscle breakdown and improving its development.
The consumption of five daily doses RECO UP5 provides 143% RDA of Vitamin B6 contributes to the normal metabolism of proteins and glycogen. It participates in energy production and promotes physical and mental wellbeing, intervening in the functioning of the immune system and energy production.
INGREDIENTS: L – Isoleucine, L – Leucine, L – Valine, L – Glutamine, Citrulline Malate, and Vitamin B6.
Packaging: 100 Capsules
DIRECTIONS: As a dietary supplement take five capsules after training or as recommended by nutritionist
DATASHEET: RECOUP5 100 CAP
LEGAL NOTE: Products reviewed here are food supplements or as established by European Directive 2002/46/EC on food supplements and all can be legally sold in all countries of the European Community, under Articles 28, 29 and 30 of the treaty the European Community and by Articles 1 to 4 of the European Parliament Decision 3052/95/EC number. Dietary supplements are not trying to replace a balanced and varied diet, are presented only in order to supplement the intake of nutrients of a normal diet. Neither treat, prevent, diagnose or cure any disease, acts attributable to drugs, as defined by European Directive 2004/27/EC of 31 March, the Council and European Parliament on medicinal products.